Reata Pharmaceuticals, Inc. - (RETA): Price and Financial Metrics
RETA Price/Volume Stats
| Current price | $172.36 | 52-week high | $172.46 |
| Prev. close | $172.32 | 52-week low | $21.83 |
| Day low | $172.32 | Volume | 1,988,500 |
| Day high | $172.46 | Avg. volume | 1,091,032 |
| 50-day MA | $158.53 | Dividend yield | N/A |
| 200-day MA | $95.04 | Market Cap | 6.58B |
RETA Stock Price Chart Interactive Chart >
RETA POWR Grades
- RETA scores best on the Quality dimension, with a Quality rank ahead of 45.4% of US stocks.
- The strongest trend for RETA is in Growth, which has been heading down over the past 121 days.
- RETA's current lowest rank is in the Stability metric (where it is better than 2.88% of US stocks).
RETA Stock Summary
- With a price/sales ratio of 279.97, REATA PHARMACEUTICALS INC has a higher such ratio than 98.68% of stocks in our set.
- RETA's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 1.24% of US stocks.
- Revenue growth over the past 12 months for REATA PHARMACEUTICALS INC comes in at 134.81%, a number that bests 95.84% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to REATA PHARMACEUTICALS INC, a group of peers worth examining would be MVIS, IPWR, AOSL, ORMP, and LSCC.
- Visit RETA's SEC page to see the company's official filings. To visit the company's web site, go to www.reatapharma.com.
RETA Valuation Summary
- RETA's price/sales ratio is 280; this is 14636.84% higher than that of the median Healthcare stock.
- RETA's price/earnings ratio has moved up 105.3 over the prior 89 months.
Below are key valuation metrics over time for RETA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| RETA | 2023-09-22 | 280.0 | 75.3 | -75.0 | -19.0 |
| RETA | 2023-09-21 | 279.7 | 75.2 | -75.0 | -19.0 |
| RETA | 2023-09-20 | 279.8 | 75.3 | -75.0 | -19.0 |
| RETA | 2023-09-19 | 279.6 | 75.2 | -74.9 | -19.0 |
| RETA | 2023-09-18 | 279.5 | 75.2 | -74.9 | -18.9 |
| RETA | 2023-09-15 | 279.5 | 75.2 | -74.9 | -18.9 |
RETA Growth Metrics
- The 3 year revenue growth rate now stands at -60.44%.
- The 3 year net cashflow from operations growth rate now stands at -181.23%.
- Its year over year net income to common stockholders growth rate is now at -14.09%.
The table below shows RETA's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-12-31 | 2.216 | -204.267 | -311.901 |
| 2022-09-30 | 3.149 | -276.773 | -311.784 |
| 2022-06-30 | 10 | -272.397 | -304.628 |
| 2022-03-31 | 11.459 | -248.875 | -303.773 |
| 2021-12-31 | 11.49 | -235.701 | -297.386 |
| 2021-09-30 | 13.748 | -157.909 | -277.777 |
RETA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- RETA has a Quality Grade of C, ranking ahead of 31.15% of graded US stocks.
- RETA's asset turnover comes in at 0.01 -- ranking 391st of 682 Pharmaceutical Products stocks.
- INVA, SUPN, and LUMO are the stocks whose asset turnover ratios are most correlated with RETA.
The table below shows RETA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.010 | 1 | 3.336 |
| 2021-03-31 | 0.012 | 1 | 4.920 |
| 2020-12-31 | 0.013 | 1 | 8.823 |
| 2020-09-30 | 0.013 | 1 | 34.641 |
| 2020-06-30 | 0.027 | 1 | 271.349 |
| 2020-03-31 | 0.042 | 1 | -40.289 |
RETA Price Target
For more insight on analysts targets of RETA, see our RETA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $226.44 | Average Broker Recommendation | 1.17 (Strong Buy) |
Reata Pharmaceuticals, Inc. - (RETA) Company Bio
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various serious or life-threatening diseases. The company was founded in 2002 and is based in Irving, Texas.
Latest RETA News From Around the Web
Below are the latest news stories about REATA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RETA as an investment opportunity.
Should You Add Reata Pharmaceuticals (RETA) to Your Portfolio?TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter investor letter. A copy of the same can be downloaded here. In the second quarter, the strategy underperformed the Russell 2000 Growth Index and returned 2.50% (net), and the index return was 7.05%. Consumer Staples, Health Care, Industrials, and Information […] |
Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.PLANO, Texas, September 21, 2023--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," "our," "us," or "we"), a global, biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that at a special meeting held today, preliminary results indicate that the stockholders of the Company voted to approve the Company’s previously announced acquisition (the "Merger") by Biogen Inc., a Delaware corporation ("Biogen"). |
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Is Expected To Breakeven In The Near FutureReata Pharmaceuticals, Inc. ( NASDAQ:RETA ) is possibly approaching a major achievement in its business, so we would... |
Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?As you may have heard this summer, Biogen (NASDAQ: BIIB) is taking out a $1.5 billion-dollar loan to fund its acquisition of rare disease drug developer Reata Pharmaceuticals (NASDAQ: RETA) for $7.3 billion in cash. Buying Reata Pharmaceuticals will accomplish a couple of things for Biogen. First, it'll gain control of Reata's newly approved drug Skyclarys, which is the only medicine approved to treat Friedreich's ataxia. |
Insider Sell: SVP, Chief Accounting Officer Bhaskar Anand Sells 406 Shares of Reata ...On September 5, 2023, Bhaskar Anand, the SVP, Chief Accounting Officer of Reata Pharmaceuticals Inc (NASDAQ:RETA), sold 406 shares of the company. |
RETA Price Returns
| 1-mo | 1.99% |
| 3-mo | 69.05% |
| 6-mo | 83.67% |
| 1-year | 585.87% |
| 3-year | 76.92% |
| 5-year | 127.18% |
| YTD | 353.70% |
| 2022 | 44.07% |
| 2021 | -78.67% |
| 2020 | -39.53% |
| 2019 | 264.40% |
| 2018 | 98.09% |
Continue Researching RETA
Want to do more research on Reata Pharmaceuticals Inc's stock and its price? Try the links below:Reata Pharmaceuticals Inc (RETA) Stock Price | Nasdaq
Reata Pharmaceuticals Inc (RETA) Stock Quote, History and News - Yahoo Finance
Reata Pharmaceuticals Inc (RETA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...